Engineered fibrin matrices for functional display of cell membrane-bound growth factor-like activities: Study of angiogenic signaling by ephrin-B2

Biomaterials

Volumn 25, Issue 16, 2004, Pages 3245-3257

  Zisch, Andreas H ^a   Zeisberger, Steffen M ^b   Ehrbar, Martin ^a   Djonov, Valentin ^c   Weber, Cornelia C ^a   Ziemiecki, Andrew ^d   Pasquale, Elena B ^e   Hubbell, Jeffrey A ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e BURNHAM INSTITUTE   (United States)

Author keywords

Biopolymer; Controlled delivery; Ephrin B2; Fibrin; Hydrogel; Therapeutic angiogenesis

Indexed keywords

CELL MEMBRANES; HYDROGELS; PROTEINS; TISSUE;

FIBRIN NETWORKS; GROWTH FACTOR SIGNALS;

BIOMATERIALS;

EPHRIN B2; EPHRIN RECEPTOR; FIBRIN; GROWTH FACTOR; LIGAND; MORPHOGEN; MUTANT PROTEIN; RECOMBINANT PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL INTERACTION; CELL MEMBRANE; CELL SURFACE; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; COVALENT BOND; DENSITY; DOSE RESPONSE; EMBRYO; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HYDROGEL; IMPLANT; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION; TECHNOLOGY;

EID: 1242317764     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2003.10.015     Document Type: Article

References (50)

1. Ferrara N., Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 5:1999;1359-1364.
2. Waltenberger J. Modulation of growth factor action. implications for the treatment of cardiovascular diseases Circulation. 96:1997;4083-4094.
3. Carmeliet P. Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries. a goal for therapeutic angiogenesis? Circ Res. 87:2000;176-178.
4. Post M.J., Laham R., Sellke F.W., Simons M. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res. 49:2001;522-531.
5. Whitaker M.J., Quirk R.A., Howdle S.M., Shakesheff K.M. Growth factor release from tissue engineering scaffolds. J Pharm Pharmacol. 53:2001;1427-1437.
6. Gale N.W., Holland S.J., Valenzuela D.M., Flenniken A., Pan L., Ryan T.E., Henkemeyer M., Strebhardt K., Hirai H., Wilkinson D.G., Pawson T., Davis S., Yancopoulos G.D. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron. 17:1996;9-19.
7. Eph Nomenclature Committee. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 1997;90:403-4.
8. Gale N.W., Yancopoulos G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases. VEGFs, angiopoietins, and ephrins in vascular development Genes Dev. 13:1999;1055-1066.
9. O'Leary D.D., Wilkinson D.G. Eph receptors and ephrins in neural development. Curr Opin Neurobiol. 9:1999;65-73.
10. Adams R.H., Klein R. Eph receptors and ephrin ligands, essential mediators of vascular development. Trends Cardiovasc Med. 10:2000;183-188.
11. Helbling P.M., Saulnier D.M., Brandli A.W. The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in Xenopus laevis. Development. 127:2000;269-278.
12. Wang H.U., Chen Z.F., Anderson D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 93:1998;741-753.
13. Gerety S.S., Wang H.U., Chen Z.F., Anderson D.J. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell. 4:1999;403-414.
14. Adams R.H., Wilkinson G.A., Weiss C., Diella F., Gale N.W., Deutsch U., Risau W., Klein R. Roles of ephrinB ligands and EphB receptors in cardiovascular development. demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis Genes Dev. 13:1999;295-306.
15. Gale N.W., Baluk P., Pan L., Kwan M., Holash J., DeChiara T.M., McDonald D.M., Yancopoulos G.D. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol. 230:2001;151-160.
16. Shin D., Garcia-Cardena G., Hayashi S., Gerety S., Asahara T., Stavrakis G., Isner J., Folkman J., Gimbrone M.A. Jr, Anderson D.J. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol. 230:2001;139-150.
17. Oike Y., Ito Y., Hamada K., Zhang X.Q., Miyata K., Arai F., Inada T., Araki K., Nakagata N., Takeya M., Kisanuki Y.Y., Yanagisawa M., Gale N.W., Suda T. Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells. Blood. 100:2002;1326-1333.
18. Stein E., Lane A.A., Cerretti D.P., Schoecklmann H.O., Schroff A.D., Van Etten R.L., Daniel T.O. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 12:1998;667-678.
19. Shireman P.K., Greisler H.P. Fibrin sealant in vascular surgery. a review J Long Term Eff Med Implants. 8:1998;117-132.
20. Chawla P.S., Keelan M.H., Kipshidze N. Angiogenesis for the treatment of vascular diseases. Int Angiol. 18:1999;185-192.
21. Pepper M.S., Montesano R., Mandriota S.J., Orci L., Vassalli J.D. Angiogenesis. a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis Enzyme Protein. 49:1996;138-162.
22. Hiraoka N., Allen E., Apel I.J., Gyetko M.R., Weiss S.J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 95:1998;365-377.
23. Fasol R., Schumacher B., Schlaudraff K., Hauenstein K.H., Seitelberger R. Experimental use of a modified fibrin glue to induce site-directed angiogenesis from the aorta to the heart. J Thorac Cardiovasc Surg. 107:1994;1432-1439.
24. Sakiyama-Elbert S.E., Hubbell J.A. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release. 65:2000;389-402.
25. Sakiyama-Elbert S.E., Panitch A., Hubbell J.A. Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J. 15:2001;1300-1302.
26. Zisch A.H., Schenk U., Schense J.C., Sakiyama-Elbert S.E., Hubbell J.A. Covalently conjugated VEGF - fibrin matrices for endothelialization. J Control Rel. 72:2001;101-113.
27. Ichinose A., Tamaki T., Aoki N. Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin. FEBS Lett. 153:1983;369-371.
28. Schense J.C., Hubbell J.A. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug Chem. 10:1999;75-81.
29. Holash J.A., Soans C., Chong L.D., Shao H., Dixit V.M., Pasquale E.B. Reciprocal expression of the Eph receptor Cek5 and its ligand(s) in the early retina. Dev Biol. 182:1997;256-269.
30. Birkenhager R., Schneppe B., Rockl W., Wilting J., Weich H.A., McCarthy J.E. Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Biochem J. 316(Part 3):1996;703-707.
31. Nikolova Z., Djonov V., Zuercher G., Andres A.C., Ziemiecki A. Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. J Cell Sci. 111:1998;2741-2751.
32. Schense J.C., Bloch J., Aebischer P., Hubbell J.A. Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension. Nat Biotechnol. 18:2000;415-419, taf/DynaPage.taf?file=/nbt/journal/ v18/n4/full/nbt0400_415.html, taf/DynaPage.taf?file=/nbt/journal/v18/n4/abs/ nbt0400_415.html.
33. Auerbach R., Kubai L., Knighton D., Folkman J. A simple procedure for the long-term cultivation of chicken embryos. Dev Biol. 41:1974;391-394.
34. Djonov V., Schmid M., Tschanz S.A., Burri P.H. Intussusceptive angiogenesis. its role in embryonic vascular network formation Circ Res. 86:2000;286-292.
35. Klein R. Excitatory Eph receptors and adhesive ephrin ligands. Curr Opin Cell Biol. 13:2001;196-203.
36. Kim I., Ryu Y.S., Kwak H.J., Ahn S.Y., Oh J.L., Yancopoulos G.D., Gale N.W., Koh G.Y. EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J. 16:2002;1126-1128.
37. Djonov V., Schmid M., Tschanz S.A., Burri P.H. Intussusceptive angiogenesis. its role in embryonic vascular network formation Circ Res. 86:2000;286-292.
38. Torres R., Firestein B.L., Dong H., Staudinger J., Olson E.N., Huganir R.L., Bredt D.S., Gale N.W., Yancopoulos G.D. PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors and their ephrin ligands. Neuron. 21:1998;1453-1463.
39. Bruckner K., Pablo Labrador J., Scheiffele P., Herb A., Seeburg P.H., Klein R. EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. Neuron. 22:1999;511-524.
40. Hattori M., Osterfield M., Flanagan J.G. Regulated cleavage of a contact-mediated axon repellent. Science. 289:2000;1360-1365.
41. Pasquale E. Neurobiology. Turning attraction into repulsion. Science. 289:2000;1308-1310.
42. Albes J.M., Klenzner T., Kotzerke J., Thiedemann K.U., Schafers H.J., Borst H.G. Improvement of tracheal autograft revascularization by means of fibroblast growth factor. Ann Thorac Surg. 57:1994;444-449.
43. Zilla P., Fasol R., Preiss P., Kadletz M., Deutsch M., Schima H., Tsangaris S., Groscurth P. Use of fibrin glue as a substrate for in vitro endothelialization of PTFE vascular grafts. Surgery. 105:1989;515-522.
44. Kang S.S., Gosselin C., Ren D., Greisler H.P. Selective stimulation of endothelial cell proliferation with inhibition of smooth muscle cell proliferation by fibroblast growth factor-1 plus heparin delivered from fibrin glue suspensions. Surgery. 118:1995;280-286. discussion 286-7.
45. Weatherford D.A., Sackman J.E., Reddick T.T., Freeman M.B., Stevens S.L., Goldman M.H. Vascular endothelial growth factor and heparin in a biologic glue promotes human aortic endothelial cell proliferation with aortic smooth muscle cell inhibition. Surgery. 120:1996;433-439.
46. Shireman P.K., Hampton B., Burgess W.H., Greisler H.P. Modulation of vascular cell growth kinetics by local cytokine delivery from fibrin glue suspensions. J Vasc Surg. 29:1999;852-861. discussion 862.=art&artType= abs&id=a97974&target=.
47. Kuhl P.R., Griffith-Cima L.G. Tethered epidermal growth factor as a paradigm for growth factor-induced stimulation from the solid phase. Nat Med. 2:1996;1022-1027.
48. Papapetropoulos A., Garcia-Cardena G., Dengler T.J., Maisonpierre P.C., Yancopoulos G.D., Sessa W.C. Direct actions of angiopoietin-1 on human endothelium. evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors Lab Invest. 79:1999;213-223.
49. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nat Biotechnol. 19:2001;1029-1034.
50. Wilting J., Christ B., Bokeloh M., Weich H.A. In vivo effects of vascular endothelial growth factor on the chicken chorioallantoic membrance. Cell Tissue Res. 274:1993;163-172.